View All Cancer Clinical Trials | The University of Kansas Cancer Center

Viewed View Trial

Open Label Phase II Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Study Type: Treatment

Phase: II

NCTID: NCT03485209

Principal Investigator: Anwaar Saeed

Viewed View Trial

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin plus Docetaxel in Triple Negative Breast Cancer NeoPACT

Study Type: Treatment

Phase: II

NCTID: NCT03639948

Principal Investigator: Priyanka Sharma

Viewed View Trial

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy

Study Type: Other

Phase: N/A

NCTID: NCT02445222

Principal Investigator: Gary Myers

Viewed View Trial

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Study Type: Treatment

Phase: III

NCTID: NCT03488693

Principal Investigator: Shane Stecklein

Viewed View Trial

A PHASE II, SINGLE ARM, MULTICENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC PATIENTS WITH RELAPSED AND REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

Study Type: Treatment

Phase: II

NCTID: NCT02228096

Principal Investigator:

Viewed View Trial

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Ind 134427 Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Study Type: Treatment

Phase: II/III

NCTID: NCT02839707

Principal Investigator: Andrea Jewell

Viewed View Trial

A Multi-national, Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 Liporaxel, Oral Paclitaxel Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer

Study Type: Treatment

Phase: II

NCTID: NCT03326102

Principal Investigator: Priyanka Sharma

Viewed View Trial

An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment

Study Type: Treatment

Phase: I

NCTID: NCT04167696

Principal Investigator: Tara Lin

Viewed View Trial

A Phase II Study of XL184 Cabozantinb win Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

Study Type: Treatment

Phase: II

NCTID: NCT04079712

Principal Investigator: Raed Al-Rajabi

Viewed View Trial

A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with Bempegaldesleukin NKTR-214 and in Combination with Bempegaldesleukin Plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

Study Type: Treatment

Phase: I/II

NCTID: NCT03435640

Principal Investigator: Joaquina Baranda

Find a Clinical Trial

Open Label Phase II Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin plus Docetaxel in Triple Negative Breast Cancer NeoPACT

Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy

Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

A PHASE II, SINGLE ARM, MULTICENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF CTL019 IN PEDIATRIC PATIENTS WITH RELAPSED AND REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

A Multi-national, Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 Liporaxel, Oral Paclitaxel Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer

A Phase II Study of XL184 Cabozantinb win Combination with Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas

A Phase I/II, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination with Bempegaldesleukin NKTR-214 and in Combination with Bempegaldesleukin Plus Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumor Malignancies

Popular Links